Abstract

BackgroundInterleukin-6 (IL-6) is a mediator of inflammation. Preclinical study of human IL biology in mouse models is limited by species-restricted signaling reactivity. Genetically modified mice are used with targeted human...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Water extract of Artemisia scoparia Waldst. & Kitam suppresses LPS-induced cytokine production and NLRP3 inflammasome activation in macrophages and alleviates carrageenan-induced acute inflammation in mice
Jong-Hwan Park ... Dong-Jae Kim
Journal of Ethnopharmacology | VOL. 268
Jong-Hwan Park, et. al.Jong-Hwan Park ... Dong-Jae Kim
23 Nov 2020
MTADV 5-MER PEPTIDE SUPPRESSES IBD PATHOLOGY AND UNVEILS A NEW POTENTIAL TARGET-SERUM AMYLOID A
Maayan Hemed-Shaked ... Jin Kim
Inflammatory Bowel Diseases | VOL. 28
Maayan Hemed-Shaked, et. al.Maayan Hemed-Shaked ... Jin Kim
22 Jan 2022
Attractive shedding
Frank R Deleo
Blood | VOL. 110
Frank R DeleoFrank R Deleo
15 Sep 2007
Meprin Metalloproteases Inactivate Interleukin 6
Timothy R Keiffer ... Judith S Bond
Journal of Biological Chemistry | VOL. 289
Timothy R Keiffer, et. al.Timothy R Keiffer ... Judith S Bond
01 Mar 2014
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers